Adding tucatinib lengthened the time before HER2-positive breast cancer progressed
In a 654-person maintenance trial, median progression-free survival was 24.9 months with tucatinib and 16.3 months with placebo. Overall survival is not known yet.

Read the original
The reporting lives at U.S. Food and Drug Administration. Our summary is checked against it, and we link it on every story.
On October 7, 2026, the FDA approved tucatinib, given with trastuzumab and pertuzumab, as maintenance treatment for adults with HER2-positive breast cancer that cannot be removed by surgery or has spread, after induction treatment. The trial, HER2CLIMB-05, enrolled 654 adults whose cancer had not grown after four to eight cycles of trastuzumab, pertuzumab, and a taxane. Some already had cancer in the brain. They were randomly assigned to tucatinib or a placebo, twice a day, while continuing trastuzumab and pertuzumab, until the cancer grew or side effects were unacceptable.
The cancer took longer to progress with tucatinib: a median of 24.9 months, compared with 16.3 months on placebo. The hazard ratio was 0.64. Overall survival numbers were not ready, so the trial has not shown that people live longer. The label carries a boxed warning for liver toxicity. It also warns about diarrhea, harm during pregnancy, and a rise in a blood-creatinine reading that does not mean the kidneys are failing. The approval covers this maintenance use. It is not a claim that the cancer is gone.
Health & Tech in MarylandSilver Spring, MarylandMedical researchCancer supportGood news on October 7
More good news
Other stories in the same neighborhood of kindness.
Health & TechFDA approves Livsayis, a four-times-a-year shot for myasthenia gravis
Livsayis is the first siRNA drug for anti-AChR-positive generalized myasthenia gravis. In a 24-week trial, 77 percent of adults improved on daily-living scores, compared with 44 percent on placebo. It carries a meningococcal infection warning.
Verified · WebMD
Health & TechFDA approves the first drug for the neurological symptoms of Type 3 Gaucher disease
Infilbray, a daily pill that reaches the brain, improved a combined coordination and thinking score versus enzyme infusions in a 52-week trial of 43 patients. Survival was not the measure.
Verified · U.S. FDA
Health & TechThe FDA approved Lembaz, the first drug shown to help infantile-onset Niemann-Pick C patients live longer
The FDA approved Lembaz, a spinal injection every two weeks. Among 36 treated patients, median survival was 8.5 years versus 4.9 in matched controls. It carries a boxed warning for hearing loss.
Verified · U.S. Food and Drug Administration